Few issues are more nettlesome in drug development than the potential for a new drug to unleash rare but potentially lethal heart-rhythm irregularities. The industry has a glaring need for improved cardiac safety testing. iCardiac Technologies hopes to turn that need into a service business with its proprietary algorithms and advanced electrocardiogram biomarkers.
150 Allens Creek Road
Rochester, NY 14618
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.
Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
